Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

CYP24A1 mutations and hypervitaminosis D

Jamie Willows and John A Sayer
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.19-1-92a
Clin Med January 2019
Jamie Willows
Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
Roles: Renal registrar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John A Sayer
Newcastle University, Newcastle upon Tyne, UK
Roles: Clinical professor of renal medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Editor – We read with interest the case report entitled ‘Risks of the ‘Sunshine pill’ – a case of hypervitaminosis D’.1 We wish to congratulate the authors on reporting this remarkable case, and hoped to make some additional contributions.

While noting that hypervitaminosis D is rare and can occur with excessively high doses of supplementation, they omit from their differential diagnoses the possibility of CYP24A1 mutations, a well-described alternate cause of the phenotype described in their patient. Loss of function mutations in CYP24A1 result in reduced action of 1,25-hydroxyvitamin-D3-24-hydroxylase, which usually inactivates active vitamin D. As well as a neonatal presentation, patients with CYP24A1 mutations can present with adult-onset hypercalcaemia, together with low parathyroid hormone levels and high urinary calcium.2,3 If this genetic condition is present, even modest vitamin D supplementation can lead to significant hypercalcaemia. Indeed, high levels of active vitamin D metabolites are found in some CYP24A1-deficient individuals even without supplementation.3

We acknowledge that in the case described by Ellis et al supplemental doses were truly high,1 but the possibility of vitamin D unmasking CYP24A1 mutations should have been considered. The identification of patients with CYP24A1 mutations is important as it allows for tailored lifestyle advice for the patient, screening of at risk family members and opens up the possibility of specific treatments targeting vitamin D production.4

In cases of hypercalcaemia, a renal tract ultrasound, looking for nephrocalcinosis, suggestive of a more longstanding kidney disorder, should be performed. Finally we would always advocate taking a detailed family history in such cases, irrespective of the patient’s age, to identify any familial pattern of renal stones, nephrocalcinosis or hypercalcaemia

  • © Royal College of Physicians 2019. All rights reserved.

References

  1. ↵
    1. Ellis S
    , Tsiopanis G, Lad T. Risks of the ‘Sunshine pill’ – a case of hypervitaminosis D. Clin Med 2018;18:311–3.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Colussi G
    , Ganon L, Penco S, et al. Chronic hypercalcaemia from inactivating mutations of vitamin D 24-hydroxylase (CYP24A1): implications for mineral metabolism changes in chronic renal failure. Nephrol Dial Transplant 2014;29:636–43.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Jobst-Schwan T
    , Pannes A, Schlingmann KP, et al. Discordant clinical course of vitamin-D-hydroxylase (CYP24A1) associated hypercalcemia in two adult brothers with nephrocalcinosis. Kidney Blood Press Res 2015;40:443–51.
    OpenUrl
  4. ↵
    1. Sayers J
    , Hynes AM, Srivastava S, et al. Successful treatment of hypercalcaemia associated with a CYP24A1 mutation with fluconazole. Clin Kidney J 2015;8:453–5.
    OpenUrlCrossRefPubMed
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
CYP24A1 mutations and hypervitaminosis D
Jamie Willows, John A Sayer
Clinical Medicine Jan 2019, 19 (1) 92-93; DOI: 10.7861/clinmedicine.19-1-92a

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
CYP24A1 mutations and hypervitaminosis D
Jamie Willows, John A Sayer
Clinical Medicine Jan 2019, 19 (1) 92-93; DOI: 10.7861/clinmedicine.19-1-92a
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Response
  • Functional disorders and chronic pain
  • A further explanation for chest pain without visible coronary artery disease
Show more Letters to the editor

Similar Articles

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians